CA3235802A1 - Compositions and methods for treating muscular dystrophy - Google Patents
Compositions and methods for treating muscular dystrophy Download PDFInfo
- Publication number
- CA3235802A1 CA3235802A1 CA3235802A CA3235802A CA3235802A1 CA 3235802 A1 CA3235802 A1 CA 3235802A1 CA 3235802 A CA3235802 A CA 3235802A CA 3235802 A CA3235802 A CA 3235802A CA 3235802 A1 CA3235802 A1 CA 3235802A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- clq
- seq
- amino acid
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163270352P | 2021-10-21 | 2021-10-21 | |
| US63/270,352 | 2021-10-21 | ||
| PCT/US2022/078510 WO2023070087A1 (en) | 2021-10-21 | 2022-10-21 | Compositions and methods for treating muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235802A1 true CA3235802A1 (en) | 2023-04-27 |
Family
ID=86059727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235802A Pending CA3235802A1 (en) | 2021-10-21 | 2022-10-21 | Compositions and methods for treating muscular dystrophy |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250230225A1 (enExample) |
| EP (1) | EP4419144A4 (enExample) |
| JP (1) | JP2024539141A (enExample) |
| CA (1) | CA3235802A1 (enExample) |
| WO (1) | WO2023070087A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117174164B (zh) * | 2023-10-30 | 2024-02-13 | 晨伫(杭州)生物科技有限责任公司 | 基于预测蛋白质-小分子结合姿势筛选先导化合物的方法 |
| EP4670793A1 (en) * | 2024-06-24 | 2025-12-31 | Montis Biosciences BV | C1Q ANTIGEN BINDING MOLECULES |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) * | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
-
2022
- 2022-10-21 WO PCT/US2022/078510 patent/WO2023070087A1/en not_active Ceased
- 2022-10-21 US US18/703,211 patent/US20250230225A1/en active Pending
- 2022-10-21 CA CA3235802A patent/CA3235802A1/en active Pending
- 2022-10-21 JP JP2024523627A patent/JP2024539141A/ja active Pending
- 2022-10-21 EP EP22884725.7A patent/EP4419144A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4419144A1 (en) | 2024-08-28 |
| JP2024539141A (ja) | 2024-10-28 |
| US20250230225A1 (en) | 2025-07-17 |
| EP4419144A4 (en) | 2026-01-14 |
| WO2023070087A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11725050B2 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| AU2016361517C1 (en) | Anti-complement factor C1q Fab fragments and uses thereof | |
| US10493148B2 (en) | PD-1 agonist antibodies and uses thereof | |
| AU2019370485B2 (en) | Compositions and methods for treating brain injury | |
| US20240059765A1 (en) | Compositions and methods for treating ocular diseases | |
| JP2026028257A (ja) | 血液障害を処置するための組成物及び方法 | |
| US20250230225A1 (en) | Compositions and methods for treating muscular dystrophy | |
| US20240034775A1 (en) | Compositions and methods for treating epilepsy | |
| KR20230087572A (ko) | 혈액 장애를 치료하기 위한 조성물 및 방법 | |
| KR20250006238A (ko) | 안구 질환을 치료하기 위한 조성물 및 방법 | |
| US20250074973A1 (en) | Compositions and methods for treating huntington’s disease | |
| EA050212B1 (ru) | Композиции и способы лечения болезней глаз | |
| CA3006092C (en) | Anti-complement factor c1q fab fragments and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20240926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241004 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20260619 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20260619 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260623 |